N/A
N=20
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
Retinal Detachment · Vitreoretinopathy Proliferative
Bottom Line
View on ClinicalTrials.gov: NCT01860586 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bevacizumab (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wills Eye
- Primary completion
- Nov 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) |
6 | — |
| SECONDARY The Effect of Intravitreal Bevacizumab Injections on the Development of Epiretinal Membranes (Increase or Decrease) |
7 | — |
Summary
The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.
Eligibility Criteria
Inclusion Criteria
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation.
Exclusion Criteria
- Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery.
- Traction retinal detachment due to proliferative diabetic retinopathy.
- Inability to flatten retina completely intraoperatively
- Known allergy or contraindication to intravitreal bevacizumab
Data sourced from ClinicalTrials.gov (NCT01860586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.